- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 491/08 - Bridged systems
Patent holdings for IPC class C07D 491/08
Total number of patents in this class: 681
10-year publication summary
|
61
|
40
|
39
|
60
|
49
|
42
|
64
|
63
|
49
|
22
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4815 |
20 |
| Merck Sharp & Dohme LLC | 3732 |
18 |
| F. Hoffmann-La Roche AG | 7841 |
15 |
| Hoffmann-La Roche Inc. | 3718 |
15 |
| Pfizer Inc. | 3370 |
14 |
| Amgen Inc. | 4362 |
14 |
| Vertex Pharmaceuticals Incorporated | 1595 |
13 |
| Epizyme, Inc. | 357 |
13 |
| Genentech, Inc. | 4087 |
12 |
| Merck Patent GmbH | 5669 |
12 |
| Zevra Therapeutics, Inc. | 95 |
10 |
| Novartis AG | 10341 |
8 |
| Boehringer Ingelheim International GmbH | 4496 |
8 |
| Rigel Pharmaceuticals, Inc. | 509 |
8 |
| Janssen Pharmaceutica N.V. | 3226 |
7 |
| Shionogi & Co., Ltd. | 867 |
7 |
| Skyhawk Therapeutics, Inc. | 145 |
7 |
| Takeda Pharmaceutical Company Limited | 2716 |
6 |
| Bodor Laboratories, Inc. | 59 |
6 |
| Kura Oncology, Inc. | 129 |
6 |
| Other owners | 462 |